HBsAg亚病毒颗粒:miRNA递送载体及潜在治疗应用

摘要/Abstract

摘要： 慢性乙型肝炎病毒(HBV)感染的治疗难点在于病毒共价闭合环状DNA(cccDNA)的持久存在和复杂的免疫逃逸机制。最新研究发现,HBV表面抗原(HBsAg)形成的亚病毒颗粒(SVP)能够选择性包裹宿主microRNA(miRNA),并通过递送至免疫细胞调控抗病毒免疫应答。研究表明,亚病毒颗粒携带的miRNA(如miR-939)可被单核细胞摄取,显著促进IL-8分泌,进而抑制IFN-α的抗病毒活性并加速肝纤维化进程。这些发现为临床诊疗提供了新思路:动态监测亚病毒颗粒-miRNA谱(如miR-939/HBsAg比值)可作为疾病进展的预测指标;靶向亚病毒颗粒-miRNA递送系统的干预策略(如siRNA修饰载体)与现有抗病毒药物联用,显示出协同治疗潜力。未来研究需要结合单细胞测序和类器官模型,进一步阐明不同感染阶段亚病毒颗粒-miRNA的时空动态变化,为开发HBV功能性治愈药物奠定基础。

关键词: 乙型肝炎病毒, 亚病毒颗粒, microRNA, 免疫逃逸, 靶向治疗

李玉龙, 张欣欣. HBsAg亚病毒颗粒:miRNA递送载体及潜在治疗应用[J]. 肝脏, 2025, 30(7): 897-900.

/ 推荐

参考文献

[1] Burki T. WHO′s 2024 global hepatitis report[J]. The Lancet. Infectious diseases,2024,24(6):e362-e363.
[2] Papatheodoridis G, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion[J]. J Hepatol. 2022,77(6):1670-1689.
[3] Iannacone M, Andreata F, Guidotti L. Immunological insights in the treatment of chronic hepatitis B[J]. Curr Opin Immunol. 2022,(8)77:102207.
[4] Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife. 2012,1:e00049.
[5] Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle[J]. Antiviral research, 2020,182:104925.
[6] Wooddell C I, Yuen M F, Chan H L, et al.?RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg[J]. Science Translational Medicine.2017,9(409):eaan0241.
[7] Le Bert N, Gill U S, Hong M, et al.. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection[J]. Gastroenterology,2020, 159(2):652-664.
[8] Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection[J]. The Journal of clinical investigation.2018, 128(10): 4573-4587.
[9] Kuipery A, GehringA J, Isogawa M. Mechanisms of HBV immune evasion[J]. Antiviral Research.2020,179,104816.
[10] Li A, Yi Z, Ma C, et al. Innate immune recognition in hepatitis B virus infection[J]. Virulence, 2025,16(1):2492371.
[11] Gehring A J. S-pecial delivery: implications of HBV surface antigen subviral particles carrying microRNA payloads[J]. Hepatology.2025,81(3):769-770.
[12] Vanlandschoot P, Van Houtte F, Hoek F, et al. Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity[J]. J Med Virol. 2003,70:513-519.
[13] Vanlandschoot P, Van Houtte F, Roobrouck A, et al. LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles[J]. J Gen Virol. 2002,83:2279-2289.
[14] Gehring A J, Ann D′Angelo J. Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cell Mol Immunol[J]. 2015,12(3):283-291.
[15] Wu X, Niu J, Shi Y. Exosomes target HBV-host interactions to remodel the hepatic immune microenvironment[J]. J Nanobiotechnology. 2024,22(1):315.
[16] Li J, Liu K, Liu Y, et al. Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity[J]. Nat Immunol. 2013,14(8):793-803.
[17] Yang Y, Han Q, Hou Z et al. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction[J]. Cell Mol Immunol. 2017,14(5):465-475.
[18] Wu Q, Glitscher M, Tonnemacher S, et al. Presence of intact hepatitis B virions in exosomes[J]. Cell Mol Gastroenterol Hepatol. 2022,15(1):237-259.
[19] Zeng W, Zheng L, Li Y, et al. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration[J]. Emerg Microbes Infect. 2024;13(1):2284286.
[20] Li J, Ma X, Xuan Q, et al. Modulation of monocyte activity by hepatocellular microRNA delivery through HBsAg particles: implications for pathobiology of chronic hepatitis B[J]. Hepatology. 2025,81(3):990-1005.
[21] Yang K, Guan S H, Zhang H, et al.. Enhanced levels of interleukin-8 are associated with hepatitis B virus infection and resistance to interferon-Alpha therapy[J]. International Journal of Molecular Sciences. 2014,15:21286-21298.
[22] Tsuge M, Hiraga N, Zhang Y, et al. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes[J]. Virology. 2018,525:48-61.
[23] Johnson Valiente A, Liem K S, Schwarz K B, et al. The inflammatory cytokine profile associated with liver damage is broader and stronger in patients with chronic hepatitis B compared to patients with acute hepatitis B[J]. The Journal of Infectious Diseases, 225(3):470-475.
[24] Hui R W, Mak L Y, Fung J et al. Prospect of emerging treatments for hepatitis B virus functional cure[J]. Clin Mol Hepatol, 2025,31(Suppl):S165-S181.
[25] Hui R W, Mak L Y, Seto W K, et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection[J]. Clin Mol Hepatol, 2022,28:408-424.
[26] Zheng P, Dou Y, Wang Q. Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity[J]. Front Cell Infect Microbiol, 2023,13:1206720.
[27] Park J J, Wong D K, Wahed A S, et al. Hepatitis B virus--Specific and global T-cell dysfunction in chronic hepatitis B[J]. Gastroenterology,2016,150:684-695.e5.
[28] Zulian V, Fiscon G, Paci P, et al. Hepatitis B virus and microRNAs: a bioinformatics approach[J]. Int J Mol Sci,2023,24(24):17224.